Invasive Micropapillary Carcinoma of the Breast
DefinitionBreast carcinoma with a prominent (pseudo) micropapillary patternDiagnostic CriteriaNumerous small pseudo-papillary clusters of cellsNo fibrovascular coresFrequent central lumen formation in clustersPeripherally located nuclei frequently bulge out with knobby appearance, "the hedgehog" tumorClusters surrounded by clear spacesOne or only a few clusters per spaceScant mucin rarely detectable in spacesSpaces surrounded by loose fibrocollagenous stromaFrequent high nuclear grade reported in some seriesFrequently has abundant eosinophilic cytoplasmFrequent lymphatic involvementOccasional psammoma bodiesAssociated DCIS...
Source: Oncopathology - March 1, 2014 Category: Pathologists Source Type: blogs
Invasive Micropapillary Carcinoma of the Breast
DefinitionBreast carcinoma with a prominent (pseudo) micropapillary patternDiagnostic CriteriaNumerous small pseudo-papillary clusters of cellsNo fibrovascular coresFrequent central lumen formation in clustersPeripherally located nuclei frequently bulge out with knobby appearance, "the hedgehog" tumorClusters surrounded by clear spacesOne or only a few clusters per spaceScant mucin rarely detectable in spacesSpaces surrounded by loose fibrocollagenous stromaFrequent high nuclear grade reported in some seriesFrequently has abundant eosinophilic cytoplasmFrequent lymphatic involvementOccasional psammoma bodiesAssociated DCIS...
Source: Oncopathology - March 1, 2014 Category: Cancer & Oncology Source Type: blogs
Laboratory Abnormalities and Pyloric Stenosis
The classic clinical presentation of infantile hypertrophic pyloric stenosis (IHPS) is an emaciated 3- to 6-week-old infant who has been experiencing immediate postprandial, nonbilious, projectile vomiting over a period of weeks. The infants remain hungry and demand to be re-fed after vomiting. Caucasian, full-term boys (4:1 to 6:1) tend to present with this condition most frequently, and these patients tend to be firstborns.
An olive-sized tumor can be felt to the right of the umbilicus, and this may best be palpable immediately after the infant has vomited. Visible peristaltic waves may also be noted. The infants are typ...
Source: M2E Too! Mellick's Multimedia EduBlog - February 28, 2014 Category: Emergency Medicine Tags: Blog Posts Source Type: blogs
Laboratory Abnormalities and Pyloric Stenosis
The classic clinical presentation of infantile hypertrophic pyloric stenosis (IHPS) is an emaciated 3- to 6-week-old infant who has been experiencing immediate postprandial, nonbilious, projectile vomiting over a period of weeks. The infants remain hungry and demand to be re-fed after vomiting. Caucasian, full-term boys (4:1 to 6:1) tend to present with this condition most frequently, and these patients tend to be firstborns.
An olive-sized tumor can be felt to the right of the umbilicus, and this may best be palpable immediately after the infant has vomited. Visible peristaltic waves may also be noted. The infants are ty...
Source: M2E Too! Mellick's Multimedia EduBlog - February 28, 2014 Category: Emergency Medicine Tags: Blog Posts Source Type: blogs
Study Reveals Significant Practice Gaps for Oncologists Treating Renal Cell Carcinoma
Conclusions
"Not recognizing predictors of poor risk or the importance of evaluating clinical symptoms can result in missed opportunities to change treatment strategy, leading to suboptimal outcomes. These results will support design of educational programs and performance improvement interventions."
As this study shows, CME is critical to healthcare provider's ongoing educational needs as they strive to stay current with the advances of medical science. Cancer treatment options like RCC demand physicians stay on top of the latest breakthroughs. Continuing medical education companies utilize innovative methodologies to o...
Source: Policy and Medicine - February 28, 2014 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
New Study Raises More Questions About the Value of Mammograms
This chart, published in British Medical Journal, shows that the breast cancer mortality of patients who underwent mammogram screening vs. those who did not is practically equal.A new, long-term study in BMJ provides perhaps the most compelling argument to date that screening mammograms may not be effective in reducing the death rate from cancer and may in fact cause harm from overtreatment in some women.
The study is based on results from the Canadian National Breast Screening Study. For this research, 89,835 women ages 40 to 59 were randomly assigned to receive either annual mammograms for five years, or no mammograms ...
Source: Our Bodies Our Blog - February 14, 2014 Category: Health Medicine and Bioethics Commentators Authors: Rachel Tags: Breast Cancer Research & Studies Source Type: blogs
Mutations in Lung Adenosquamous Carcinomas
Journal of Thoracic Oncology just issued a published ahead-of-print article that examined mutations of most frequent driver mutations seen in pulmonary adenocarcinomas in a series of 76 resected adenosquamous carcinomas of the lung. This is an important study to note... (Source: The Daily Sign-Out)
Source: The Daily Sign-Out - January 31, 2014 Category: Pathologists Authors: Mark D. Pool, M.D. Tags: Lung adenocarcinoma Lung Cancer Molecular Pathology Source Type: blogs
Trip in systematic reviews
Trip is mentioned thousands of times in articles in Google Scholar (click here) and in the last year over 300 times (click here). Most of these are systematic reviews and I found two new articles today, these were:Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literatureTrauma center performance evaluation based on costs: A systematic review of cohort studies Needless to say Trip was not alone and other databases mentioned in these SRs were: PubMed Medline Cochrane Library Google Scholar EMBASE Web of Science C...
Source: Liberating the literature - January 26, 2014 Category: Technology Consultants Source Type: blogs
One Doctor's Confession: Basal And Squamous Cell Skin Cancers Are NOT Benign
I have made a resolution for 2014: I will never, never, never again call basal and squamous skin cancers "benign" cancers.
Why would I make such a strange commitment? The explanation is simple: I spent 4 hours on New Year's Eve sitting in the surgeon's chair getting a skin cancer taken off my nose. Nothing about the experience fits the "benign" label so many professionals, including yours truly, have used: routine; easy to treat; nothing to worry about. Friends, after this experience, which left me looking like a tall, white-haired Rudolph the Reindeer, I am here to tell you these cancers are not to be tr...
Source: Dr. Len's Cancer Blog - January 7, 2014 Category: Cancer Authors: Dr. Len Tags: Cancer Care Early detection Environment Exercise Other cancers Prevention Screening Treatment Source Type: blogs
Hepatitis C in Egypt
The following background data on Hepatitis C in Egypt are abstracted from Gideon www.GideonOnline.com and the Gideon e-book series. [1,2] Primary references available on request.
Incidence and Prevalence:
Hepatitis C is the most common cause of chronic liver disease in Egypt. The nationwide carriage rate in 1997 was estimated at 6 to 8 million, or 18.1% of the population – the highest rate in the world.
A study published in 2010 estimated the yearly rate at 500,000 new cases (0.7% of the population); while a study published in 2013 estimated the yearly rate at fewer than 150,000 cases. An analysis published in 2...
Source: GIDEON blog - December 19, 2013 Category: Databases & Libraries Authors: Dr. Stephen Berger Tags: Ebooks Epidemiology ProMED Egypt hepatitis c Source Type: blogs
FDA official: “clinical trial system is broken” - BMJ
FDA investigator Thomas Marciniak has spoken out over drug companies and missing or “bad” data, most famously over rosiglitazone. He tells Deborah Cohenhow he believes the current research and development process is brokenThe clinical trial system is broken and it’s getting worse, according to longstanding Food and Drug Administration investigator, Thomas Marciniak.For seasoned observers of the drug approval process, Marciniak will be a familiar name and his comments will come as little surprise. In his 11 years at the US federal agency, Marciniak has been embroiled in high profile controversies that have pitted...
Source: PharmaGossip - December 9, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
Let's talk about cancer.
Three years ago at this time I was lying on the couch, watching St. Elmo's Fire with Friend Pens The Lotion S., feeling rather giddy from a combination of red wine and Vicodin. I had just had the majority of my hard palate and all of my soft palate removed due to a case of oral cancer. If you want to read the whole story, go back to September of 2010 in the archives.(St. Elmo's Fire is a good movie filled with terrible people. Skip it; that way, you won't have to wish for that two hours of your Vicodin- and red-wine-soaked life back.)Let's talk about oral cancers. There are a lot of them, some of them frightening, some of ...
Source: Head Nurse - October 30, 2013 Category: Nurses Authors: Jo Source Type: blogs
Where Are Those Royalties? NYU Claims Pfizer Is A Deadbeat
In a bid to retrieve tens of millions of dollars over the next several years, New York University has filed a lawsuit against Pfizer, claiming the drugmaker failed to pay royalties on its Xalkori medication, which was approved two years ago by the FDA to treat non-small cell lung cancer along with a diagnostic kit.
The dispute is the latest example of a spat over the proceeds from research that is generated by academia but is commercialized by a drugmaker under a development deal. In this instance, NYU claims that Pfizer did not honor an agreement that was inherited as part of its 2003 acquisition of Pharmacia.
The agreeme...
Source: Pharmalot - October 22, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
New nanopharmaceutical may help overcome resistance to specific anticancer drugs
Conclusions: Results generated through this translational research plan suggest that CRLX101 can overcome HIF-1α-mediated acquired resistance to antiangiogenic drugs, assisting the use of CRLX101 in combination with antiangiogenic medicines as an exciting new paradigm for the treatment of cancer.
Related Posts:Cleveland Clinic’s preventive breast cancer vaccine…Harvard Stem Cell Institute publishes initial clinical trialImportant advance in the fight against skin cancerNew IBS treatment shows possible in Phase 2 researchNew blood test could help millions of patients with&hellip...
Source: My Irritable Bowel Syndrome Story - October 21, 2013 Category: Other Conditions Authors: Ken Tags: IBS News Source Type: blogs
